Philip Dunn, DO
Rheumatology · Allentown, PANPI 1962847772
Payments from drug & device makers
Across 709 payments — averaging $118.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$39K
- AbbVie$38K
- Novartis$1K
- UCB, Inc.$1K
- AstraZeneca$804
- Pfizer$718
- plus $3K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 282 | $39,308 |
| AbbVie | 124 | $38,046 |
| Novartis | 38 | $1,258 |
| UCB, Inc. | 62 | $1,199 |
| AstraZeneca(2 entities) | 27 | $804 |
| Pfizer | 44 | $718 |
| Johnson & Johnson(3 entities) | 15 | $435 |
| Lilly USA, LLC | 15 | $361 |
| Sobi, Inc | 18 | $334 |
| GSK | 14 | $240 |
| Boehringer Ingelheim | 9 | $213 |
| Janssen Scientific Affairs, LLC | 2 | $209 |
| Bristol Myers Squibb | 10 | $171 |
| Collegium Pharmaceutical, Inc. | 14 | $125 |
| Aurinia Pharma U.S., Inc. | 5 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $100 |
| Genentech USA, Inc. | 6 | $91 |
| Radius Health, Inc. | 5 | $86 |
| Pacira Therapeutics, Inc. | 5 | $72 |
| Sanofi | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
| Organon | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Sandoz | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $13 |
How this compares
$84,123 in reported general payments places this provider in the 80th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Allentown
- Alan KivitzDuncansville$27.1M
- Peter MerkelRadnor$6.3M
- Rohit AggarwalPittsburgh$6.2M
- Alexis Ogdie-BeattyPhiladelphia$5.7M
- Jonathan MinerPhiladelphia$3.8M
- Siamak Moghadam-KiaPittsburgh$1.9M
- Frederick MurphyDuncansville$1.2M
- Gregory EmkeyWyomissing$1.2M
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.